Anc80L65-trastuzumab

N/A

Report date: 2025/01/26 17:19:34

Base Information

Drug NameAnc80L65-trastuzumab

Drug Alias NameAAV Anc80L65-based gene therapy encoding trastuzumab (Affinia Therapeutics)brain-directed AAV-encoded anti-HER2 antibody (Affinia Therapeutics)brain-directed AAV-encoded trastuzumab (Affinia Therapeutics)AFTX-002

ClassificationBiologics

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBrain Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAffinia Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAffinia Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsBrain Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A